Sponsors (8)
The bill increases federal attention, coordination, and research capacity for PKD — likely speeding better diagnostics and treatments and lowering long‑term Medicare costs — but it raises short‑term federal spending, can divert resources from other priorities, may create public–private data/IP tensions, and could be used to justify coverage restrictions that harm patients.
People with polycystic kidney disease (PKD) — ~500,000 Americans — are likely to gain faster development and earlier access to improved PKD diagnostics and treatments because the bill expands and coordinates NIH-funded basic, translational, and clinical research, encourages public–private efforts, and promotes AI/precision approaches.
By identifying PKD as a high‑cost driver of end‑stage renal disease and promoting prevention-focused research, the bill could lower long‑term Medicare spending and reduce future dialysis/transplant needs for Medicare beneficiaries.
The bill builds research and clinical capacity — expanding training opportunities and creating a coordinated research roadmap — which strengthens the PKD clinical/research workforce and improves care quality over time.
Policymakers could use PKD's large Medicare cost footprint to justify cost‑containment actions (reduced benefits, stricter coverage rules, or prior authorization) that would directly restrict access to expensive but necessary dialysis, transplants, or drugs for PKD patients.
Shifting NIH priorities and coordinated focus on PKD risks diverting limited research funds and investigator attention away from other diseases, potentially slowing progress for other patient groups and straining research capacity.
Expanding NIH research priorities and public–private initiatives will likely increase federal spending, which could add pressure on taxpayers and on competing budget priorities.
Based on analysis of 3 sections of legislative text.
Directs NIH to expand, coordinate, and prioritize research and training on polycystic kidney disease and to produce a PKD research roadmap within 24 months.
Official title: To support polycystic kidney disease research, and for other purposes.
Introduced June 4, 2026 by Debbie Wasserman Schultz · Last progress June 4, 2026
Establishes new, focused NIH responsibilities to expand research on polycystic kidney disease (PKD), including basic, translational, and clinical studies, training programs, and coordination with federal, academic, and private partners. Requires the NIH Director to create and convene a working group to produce a comprehensive PKD research and innovation roadmap and to report findings and recommended timelines to Congress within 24 months. Directs the Institute director to prioritize PKD proposals most likely to accelerate understanding and treatment, to support workforce development for PKD research, and to promote public–private collaboration and advanced technologies such as AI and precision medicine in PKD research planning.